There are two main projects in the PharmNovo pipeline:
Our focus is on PN6047, a novel potent and selective, biased delta-opioid receptor agonist, which is predicted to reduce chronic pain and combat other conditions involving sensory hypersensitivity, including chronic cough and itch.
In pre-clinical studies, PN6047 has shown high potency and efficacy in reducing chronic pain without any indications of unwanted morphine-like side effects.
PN6047 has an excellent pre-clinical safety profile and fully medicine-like properties predicting favorable dosing in humans. Its metabolic profile also indicates possibilities for developing combination therapies.